Katelyn K Jetelina1,2, Christian Carr3, Caitlin C Murphy4, Navid Sadeghi5,6, Jayanthi S Lea7, Jasmin A Tiro4. 1. Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth Science Center at Houston, School of Public Health, 6011 Harry Hines Blvd, V8.106C, Dallas, TX, USA. katelyn.k.jetelina@uth.tmc.edu. 2. Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. katelyn.k.jetelina@uth.tmc.edu. 3. Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth Science Center at Houston, School of Public Health, 6011 Harry Hines Blvd, V8.106C, Dallas, TX, USA. 4. Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. 5. Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 6. Parkland Health and Hospital System, Dallas, TX, USA. 7. Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
PURPOSE: Characterize prevalence of intimate partner violence (IPV) among breast and cervical survivors receiving care in an urban safety-net healthcare system; Examine the relationship between IPV and clinical characteristics, receipt of cancer treatment, and guideline-recommended survivorship care. METHODS: From 2010 to 2017, breast and cervical cancer survivors were identified and recruited from a large, integrated, safety-net hospital system. Electronic health records (EHR; to measure survivorship care), cancer registry (to measure clinical characteristics), and patient telephone surveys (to measure IPV) were triangulated among 312 survivors. Bivariate and multivariable models assessed the relationship between victimization and clinical characteristics, cancer treatment, and guideline-recommended survivorship care. RESULTS: Among the 312 participants, 54% identified as IPV+. Among breast cancer, IPV+ cancer participants were twice more likely to develop estrogen receptor negative ER- and/or progesterone receptor negative PR- tumor receptors compared with IPV- cancer participants (AOR = 2.31; 95% CI, 1.20, 4.44). IPV+ breast cancer participants were less likely to have surgery and less likely to have hormone therapy as a first course of treatment compared with IPV- participants. There was no relationship between IPV and adherence to guideline-recommended cancer survivorship care. CONCLUSIONS: This study expands our current knowledge on how victimization, and specifically IPV, impact health among specialty care. Future research should determine the feasibility of implementing Trauma-Informed Care in oncology practices to better optimize care. IMPLICATIONS FOR CANCER SURVIVORS: At integrated hospital systems, IPV+ cancer participants should utilize social workers, within their oncology clinics, to connect to victim services.
PURPOSE: Characterize prevalence of intimate partner violence (IPV) among breast and cervical survivors receiving care in an urban safety-net healthcare system; Examine the relationship between IPV and clinical characteristics, receipt of cancer treatment, and guideline-recommended survivorship care. METHODS: From 2010 to 2017, breast and cervical cancer survivors were identified and recruited from a large, integrated, safety-net hospital system. Electronic health records (EHR; to measure survivorship care), cancer registry (to measure clinical characteristics), and patient telephone surveys (to measure IPV) were triangulated among 312 survivors. Bivariate and multivariable models assessed the relationship between victimization and clinical characteristics, cancer treatment, and guideline-recommended survivorship care. RESULTS: Among the 312 participants, 54% identified as IPV+. Among breast cancer, IPV+ cancerparticipants were twice more likely to develop estrogen receptor negative ER- and/or progesterone receptor negative PR- tumor receptors compared with IPV- cancerparticipants (AOR = 2.31; 95% CI, 1.20, 4.44). IPV+ breast cancerparticipants were less likely to have surgery and less likely to have hormone therapy as a first course of treatment compared with IPV- participants. There was no relationship between IPV and adherence to guideline-recommended cancer survivorship care. CONCLUSIONS: This study expands our current knowledge on how victimization, and specifically IPV, impact health among specialty care. Future research should determine the feasibility of implementing Trauma-Informed Care in oncology practices to better optimize care. IMPLICATIONS FOR CANCER SURVIVORS: At integrated hospital systems, IPV+ cancerparticipants should utilize social workers, within their oncology clinics, to connect to victim services.